This trial is evaluating whether SEL24/MEN1703 will improve 1 primary outcome and 1 secondary outcome in patients with Leukemia, Myeloid. Measurement will happen over the course of DLTs in patients during their first 21-day treatment cycle.
This trial requires 68 total participants across 1 different treatment group
This trial involves a single treatment. SEL24/MEN1703 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
"An enlarged liver and an enlarged spleen are common, but leukemic cells do not usually accumulate in the spleen or liver. Most patients have bone loss. Atypical features of myelogenous leukemia include hepatosplenomegaly, pancytosis, and blast hyperplasia. Atypical features of acute lymphoblastic leukemia include lymphadenopathy, splenomegaly, and splenic infiltration. Atypical features of acute myelogenous leukemia include anemia, thrombocytopenia, leukopenia, and hyperbasophilia." - Anonymous Online Contributor
"Patients were treated mainly with corticosteroids, inducible antithreonoglobulin, and chemotherapy for acute leukemia. Newer drugs such as proteasome inhibitors and imatinib were used to treat chronic lymphocytic leukemia and chronic myeloid and acute myeloid leukemia." - Anonymous Online Contributor
"Acute myeloid leukemia accounts for approximately one-third of all new leukemias diagnosed annually in Japan. The majority of the patients have low or normal levels of white cell count and no abnormalities in hematopoietic progenitors. The high-risk group of AML with more than 20% blasts may receive a high risk of prognosis and/or chemotherapeutic treatment should be indicated for them." - Anonymous Online Contributor
"Can leukemias, myeloid, acute be cured? answer: It is possible in some instances to achieve a complete remission of disease and long-term survival. The optimal timing and methods for obtaining these results are undefined." - Anonymous Online Contributor
"In 1999, approximately 30000 new cases of leukemias and neutropenias and 3500 cases of CLL, AL, AML, and HL were diagnosed in the United States. AML occurred at a rate that was similar to but much higher than that for most of the other leukemias and HL. In contrast to Western nations, there continues to be important racial differences in the American incidence of leukemia, myeloid, acute." - Anonymous Online Contributor
"Leukemia, myeloid/acute, is caused by abnormal development in the formation of blood cell precursors in the bone marrow. It is usually caused by one of two mechanisms, hematopoietic stem cell (HSC) mutations or abnormal signaling. In both instances, exposure to ionizing radiation or to chemotherapy can cause leukemia or myeloid/acute. Lymphoma, leukemic, is caused by a malignancy of B cells or T cells. It can be acquired or de novo and is related to a variety of health problems. Myeloma, myeloid/lymphoid, is caused by the clonal recruitment of malignant light chains into bone marrow." - Anonymous Online Contributor
"In case of acute leukemia, a person's overall survival is usually good with aggressive treatments (Bone Marrow Transplantation, Bone Marrow Transplant HCT [Hematopoietic Cell Transplantation], or HCT BMT) being common. But some of these treatments have significant side effects. A recent study estimated that the chance of developing leukemia, myeloid, acute in the future is about 4.2% after five years. With this number, it is important to be aware before participating in a clinical trial, so that you know some of the treatment options. If you want to join a clinical trial, [withpower.com](https://www.power." - Anonymous Online Contributor
"To conduct additional prospective studies or clinical trials, patients should not exclude themselves purely based on their age or the presence of comorbidities (such as lung disease, alcoholism, or diabetes), but take into special account individual risks associated with both treatment and the risks of the disease itself. We should ensure that we know which treatment will be effective for whom; we must therefore be aware of the possibility of bias, due to a choice between a treatment and a patient based on a number of factors." - Anonymous Online Contributor
"There are several common events that lead to the development of leukemia, myeloid, acute, which are not exclusive to this disease. To improve survivability, patients requiring chemotherapy should be managed as a whole to address a patient's primary etiology." - Anonymous Online Contributor
"Data from a recent study showed a higher rate of MAF amongst families with a history of AML, highlighting the importance of further research into its genetic, familial clustering, and environmental aetiology." - Anonymous Online Contributor
"Results from a recent paper supports the idea that patients with AML, MCL, and ALL at their acute stage have a better survival rate compared with patients who have their leukemia in chronic stage. Moreover, AML patients who present with a normal and stable neutrophil count have a significantly longer survival rate compared with patients of chronic AML. The prognostic factors for survival are, in order of significance, gender (male), age, time from disease diagnosis (diagnosed <3 yr ago), and age at AML diagnosis (<61 yr)." - Anonymous Online Contributor
"The data suggest that Sel24/Meneh1703 is well tolerated in men with castration resistant prostate cancer. Longer-term study is now required to confirm these results and investigate the potential for this treatment to be effective for people with castration resistant prostate cancer." - Anonymous Online Contributor